This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CSL Behring International Trial Shows Clinical Efficacy Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) For Once Weekly Prophylaxis In Patients With Severe Hemophilia B

AMSTERDAM, July 3, 2013 /PRNewswire/ -- Data presented by CSL Behring today showed clinical efficacy of a once-weekly dosing regimen of recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP). Results of the study were presented during an oral session at the International Society on Thrombosis and Haemostasis (ISTH) congress in Amsterdam.

(Logo: )

CSL Behring, in collaboration with its parent company, CSL Limited (ASX: CSL), is developing rIX-FP for the prophylaxis and treatment of bleeding episodes in patients with hemophilia B as part of the PROLONG-9FP clinical study program.

"Hemophilia B is characterized by factor IX deficiency, which prevents normal blood clotting. People with this condition require factor IX infusions two to three times a week to achieve a significant reduction in bleeding," said Professor Uri Martinowitz, Director of the Institute of Thrombosis and Hemostasis and the Israeli National Hemophilia Center at Chaim Sheba Medical Center in Tel Hashomer, Israel. "This trial showed that less frequent infusions were needed with CSL Behring's investigational rIX-FP compared to currently available FIX products used on-demand or prophylactically to prevent or treat bleeding episodes."

The trial enrolled 17 hemophilia B patients, 13 of whom received weekly prophylactic treatment for approximately 11 months, and four of whom received on-demand treatment only when bleeding occurred. All prophylaxis patients maintained weekly treatment for the entire study, with mean and median annualized spontaneous bleeding rates of 1.26 and 1.13, respectively. All bleeding was treated successfully with two or fewer infusions of rIX-FP, with 95.3 percent of events treated with a single infusion.  

Following a single infusion of 25 IU/kg rIX-FP, the mean FIX activity level was 3.8 percent and 2.7 percent above baseline at day 7 and 14, respectively, and the half-life (time taken for half of the treatment to be eliminated or metabolized) of rIX-FP was 94 hours.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs